| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.079.921 |
| Chemical and physical data | |
| Formula | C7H7ClN6O2 |
| Molar mass | 242.62 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Mitozolomide (INN) is anantineoplastic. It is animidazotetrazine derivative.
Development of mitozolomide was discontinued duringPhase IIclinical trials after it was found to cause severe and unpredictablebone marrow suppression.[1]Temozolomide, which has been in clinical use since 1999, is a less toxicanalogue of mitozolomide.[2]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |